453 related articles for article (PubMed ID: 18544963)
1. The molecular pathology of hereditary breast cancer.
Palacios J; Robles-Frías MJ; Castilla MA; López-García MA; Benítez J
Pathobiology; 2008; 75(2):85-94. PubMed ID: 18544963
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Sánchez L; Rivas C; Benítez J
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3606-14. PubMed ID: 14506147
[TBL] [Abstract][Full Text] [Related]
3. Histopathology of BRCA1- and BRCA2-associated breast cancer.
Honrado E; Benítez J; Palacios J
Crit Rev Oncol Hematol; 2006 Jul; 59(1):27-39. PubMed ID: 16530420
[TBL] [Abstract][Full Text] [Related]
4. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer.
Pinilla SM; Honrado E; Hardisson D; Benítez J; Palacios J
Breast Cancer Res Treat; 2006 Sep; 99(1):85-90. PubMed ID: 16541313
[TBL] [Abstract][Full Text] [Related]
5. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study.
Armes JE; Trute L; White D; Southey MC; Hammet F; Tesoriero A; Hutchins AM; Dite GS; McCredie MR; Giles GG; Hopper JL; Venter DJ
Cancer Res; 1999 Apr; 59(8):2011-7. PubMed ID: 10213514
[TBL] [Abstract][Full Text] [Related]
6. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes.
Loman N; Johannsson O; Bendahl PO; Borg A; Fernö M; Olsson H
Cancer; 1998 Jul; 83(2):310-9. PubMed ID: 9669814
[TBL] [Abstract][Full Text] [Related]
7. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.
Arnes JB; Brunet JS; Stefansson I; Bégin LR; Wong N; Chappuis PO; Akslen LA; Foulkes WD
Clin Cancer Res; 2005 Jun; 11(11):4003-11. PubMed ID: 15930334
[TBL] [Abstract][Full Text] [Related]
8. The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications.
Honrado E; Benítez J; Palacios J
Mod Pathol; 2005 Oct; 18(10):1305-20. PubMed ID: 15933754
[TBL] [Abstract][Full Text] [Related]
9. Hereditary breast cancer: part II. Management of hereditary breast cancer: implications of molecular genetics and pathology.
Silva E; Gatalica Z; Snyder C; Vranic S; Lynch JF; Lynch HT
Breast J; 2008; 14(1):14-24. PubMed ID: 18086271
[TBL] [Abstract][Full Text] [Related]
10. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
Joosse SA; Brandwijk KI; Devilee P; Wesseling J; Hogervorst FB; Verhoef S; Nederlof PM
Breast Cancer Res Treat; 2012 Apr; 132(2):379-89. PubMed ID: 20614180
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic analysis of BRCA1- or BRCA2-associated hereditary breast carcinoma in Japanese women.
Noguchi S; Kasugai T; Miki Y; Fukutomi T; Emi M; Nomizu T
Cancer; 1999 May; 85(10):2200-5. PubMed ID: 10326698
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers.
Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Dopazo J; Rivas C; Benítez J
Breast Cancer Res Treat; 2005 Mar; 90(1):5-14. PubMed ID: 15770521
[TBL] [Abstract][Full Text] [Related]
13. Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.
Aaltonen K; Blomqvist C; Amini RM; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H
Clin Cancer Res; 2008 Apr; 14(7):1976-83. PubMed ID: 18381935
[TBL] [Abstract][Full Text] [Related]
14. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
[TBL] [Abstract][Full Text] [Related]
15. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
[TBL] [Abstract][Full Text] [Related]
16. Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping.
Oldenburg RA; Kroeze-Jansema K; Meijers-Heijboer H; van Asperen CJ; Hoogerbrugge N; van Leeuwen I; Vasen HF; Cleton-Jansen AM; Kraan J; Houwing-Duistermaat JJ; Morreau H; Cornelisse CJ; Devilee P
Clin Cancer Res; 2006 Mar; 12(6):1693-700. PubMed ID: 16551851
[TBL] [Abstract][Full Text] [Related]
17. Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics.
Zuradelli M; Peissel B; Manoukian S; Zaffaroni D; Barile M; Pensotti V; Cavallari U; Masci G; Mariette F; Benski AC; Santoro A; Radice P
Breast Cancer Res Treat; 2010 Nov; 124(1):251-8. PubMed ID: 20373018
[TBL] [Abstract][Full Text] [Related]
18. CGH analysis of familial non-BRCA1/BRCA2 breast tumors and mutation screening of a candidate locus on chromosome 17q11.2-12.
Maguire P; Holmberg K; Kost-Alimova M; Imreh S; Skoog L; Lindblom A
Int J Mol Med; 2005 Jul; 16(1):135-41. PubMed ID: 15942690
[TBL] [Abstract][Full Text] [Related]
19. Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization.
Jönsson G; Naylor TL; Vallon-Christersson J; Staaf J; Huang J; Ward MR; Greshock JD; Luts L; Olsson H; Rahman N; Stratton M; Ringnér M; Borg A; Weber BL
Cancer Res; 2005 Sep; 65(17):7612-21. PubMed ID: 16140926
[TBL] [Abstract][Full Text] [Related]
20. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype.
Heikkinen T; Kärkkäinen H; Aaltonen K; Milne RL; Heikkilä P; Aittomäki K; Blomqvist C; Nevanlinna H
Clin Cancer Res; 2009 May; 15(9):3214-22. PubMed ID: 19383810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
